AQST250516C10000
- 0.05
- 0.000.00%
Aquestive Therapeutics Newsroom
Earnings Preview: AQST to Report Financial Results Post-market on May 12
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Aquestive Therapeutics Announced Topline Results From Its Pediatric Study For Anaphylm (Epinephrine) Sublingual Film In Patients Aged 7 To 17 And Weighing Over 30kgs With A Personal History Of Allergic Reactions, FDA Application Acceptance Expected In...
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Aquestive Therapeutics Advances Product Pipeline and Market Access
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Buy Rating on Aquestive Therapeutics Driven by Anaphylm's Regulatory Progress and Strategic Launch Preparations
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts
Aquestive Therapeutics Price Target Cut to $8.00/Share From $10.00 by Lake Street
Aquestive Therapeutics Analyst Ratings
Raymond James Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $7
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $8
Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)
A. G. P. Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $4.75
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Earnings Call Summary | Aquestive Therapeutics(AQST.US) Q4 2024 Earnings Conference
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
Aquestive Therapeutics Q4 Net Loss Widens, Revenue Falls; 2025 Revenue Outlook Issued
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics